BioNTech (NASDAQ:BNTX) shares declined 5% on Tuesday after the biotechnology company reported that its investigational mRNA ...

Every $10,000 held in BioNTech SE (NASDAQ: BNTX) shrank by roughly $713 after the Company announced that its Phase 2/3 ...

Is bigger always better? Not necessarily.

BioNTech (NASDAQ: BNTX) shares fell 5% on Tuesday after the company announced that a mid-to-late-stage clinical trial for its experimental mRNA cancer drug, BNT113, missed its first major goal.

AHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy ...

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly ...

Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...

Multiple milestones achieved in 2026, including initiation of six pivotal trials - five for pumitamig and one for B7-H3-targeting ADC candidate elfetabart drozuntecan; upcoming 2026 catalysts include ...

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, ...

BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates BioNTech co-founders Ugur Sahin and Özlem Türeci will ...

High-rolling investors have positioned themselves bullish on BioNTech (NASDAQ:BNTX), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...

Engitix has appointed Ryan Richardson as an Independent Non-Executive Director as the biotechnology company advances its ...